Pilot Study of Atorvastatin and Anakinra in Children With Coronary Artery Abnormalities Secondary to Kawasaki Disease
Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · Feb 6, 2021
Trial Information
Current as of July 21, 2025
Active, not recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of two medications, atorvastatin and anakinra, on children who have experienced Kawasaki disease (KD) and have developed problems with their coronary arteries. Kawasaki disease is a condition that can cause serious heart issues in children, and even with treatment, some children still face risks of heart complications later in life. The trial aims to see if using these two medications together can help reduce inflammation in the coronary arteries and prevent further damage.
To participate in this study, children need to be diagnosed with acute Kawasaki disease and have specific measurements indicating early problems with their coronary arteries. The trial is currently active but not recruiting new participants, and it is open to children aged one year to around 17 years, regardless of gender. Participants will receive the combination of atorvastatin and anakinra, both of which have been shown to be safe for children with Kawasaki disease. This study is important because it may offer a new way to protect the heart health of children affected by this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Acute Kawasaki disease with a Z score of 3 or larger of the LAD or RCA
- Exclusion Criteria:
- • Taking a CYP3A4 metabolized drug (such as cyclosporine)
About University Of California, San Diego
The University of California, San Diego (UCSD) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust focus on translational medicine, UCSD leverages its interdisciplinary approach to explore groundbreaking therapies and interventions across a wide range of medical fields. The university's state-of-the-art facilities and collaboration with top-tier faculty and researchers ensure a comprehensive and ethical framework for conducting clinical trials, ultimately aiming to enhance patient outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
San Diego, California, United States
Patients applied
Trial Officials
Adriana Tremoulet, MD
Principal Investigator
Professor
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials